**Table 1 - ICP Performance Measures** 

#	Performance Measure	Specification	Quality	P4P	Yrl	Yr2	Yr3
		Source	Monitoring				
1	Behavioral Health Risk Assessment and Follow-up						
	1) Behavioral Screening/ Assessment within 60 days of enrollment	State	X				
	2) Behavior Health follow-up within 30 days of screening	State	X				
2	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET)	HEDIS®	Х				
3	Follow-Up with a Provider within 30 Days After an Initial Behavioral Health Diagnosis	State	Х	Х	Х	Х	Х
4	Follow-Up After Hospitalization for Mental Illness (FUH)						
	Follow-up in 7 days	HEDIS®	Х				
	Follow-up in 30 days	HEDIS®	Х	Х	Χ	Х	Х
5	Care Coordination - Influenza Immunization Rate	State	Х				
6	Annual Dental Visit						
	Annual Dental Visit -All	State	Х				
	Annual Dental Visit-DD only	State	Х	Х	Χ	Х	X
7	Dental ER Visit	State	Х				
8	Comprehensive Diabetes Care (CDC) (Measure 8A-8C): Meet two Measures out of Measures 8A-8C						
	A) HbA1 c testing 1 x per year	HEDIS®	Х	Х	Х	Х	Х
	B) Microalbuminuria testing 1 X per year	HEDIS®	Х	Х	Х	Х	Х
	C) Cholesterol testing 1X per year	HEDIS®	Х	Х	Х	Х	Х
	DD Waiver Program Support -Services for Enrollees in DD Waiver and Enrollees with DD Diagnostic History - HbAI c testing 1x per year	HEDIS®	Х				
	Comprehensive Diabetes Care Administrative						
	Method (Measure 8D-8E): Meet one Measure out of						
	Measures 8D and 8E						
	D) Statin Therapy 80% of the time	State	X	Х	Х	Х	Х
	E) ACE/ARB 80% of the time	State	Х	Х	Х	Х	Х
9	Congestive Heart Failure (Measure 9A-9C): Meet two						
	Measures out of Measures 9A-9C			,,,			
	A) ACE/ARB 80% of the time	State	X	X	X	X	Х
	B) Beta Blocker 80% of the time	State	X	X	X	X	Х
1.5	C) Diuretic 80% of the time	State	Х	Х	Х	Х	Х
10	Coronary Artery Disease (Measure 10A-10C): Meet						
	two measures out of Measures 10A-10D						

#	Performance Measure	Specification Source	Quality Monitoring	P4P	Yrl	Yr2	Yr3
	A) Cholesterol testing 1X per year	State	Х	Х	Х	Х	Х
	B) Statin Therapy 80% of the time	State	Х	Х	Х	Х	Х
	C) ACE/ARB 80% of the time	State	Х	Х	Х	Х	Х
	D) Persistence of Beta Blocker Treatment After Heart Attack (PBH)	HEDIS®	Х	Х	X	X	X
11	Pharmacotherapy Management of Chronic Obstructive Pulmonary Disease Exacerbation (PCE) (Measure 11A-11B): Meet two Measures out of Measures 11 A-11C						
	A) Acute COPD Exacerbation w/corticosteroid	HEDIS®	Х	Х	Х	Х	Х
	B) History of hospitalizations for COPD with a bronchiodilator medications	HEDIS®	Х	Х	Х	Х	Х
	C) Use of Spirometry Testing in the Assessment and Diagnosis of COPD(SPR)	HEDIS®	Х	Х	Х	X	Х

#	Performance Measure	Specification Source	Quality Monitoring	P4P	Yrl	Yr2	Yr3
12	Ambulatory Care (AMB)	HEDIS®	X	X	X	Χ	X
	1) Waiver Program Support - Services for Population in DD Waiver and Clients with Diagnostic History- Emergency Department Utilization Rate per 1,000	HEDIS®	Х				
13	Ambulatory Care Follow-Up with a Provider within 14 Days of Emergency Department (ED) Visit	State	Х	X	Х	X	X
14	Inpatient Utilization- General Hospital/ Acute Care (IPU)	HEDIS®	Х				
15	Mental Health Utilization (MPT)	HEDIS®	Х				
16	Ambulatory Care Follow-Up with a Provider within 14 Days of Inpatient Discharge	State	Х	Х	Х	Х	Х
17	A) Inpatient Hospital 30-Day Readmission Rate	State	Х				
	B) Inpatient Mental Hospital 30-Day Readmission Rate	State	Х				
18	Long Term Care Urinary Tract Infection Admission Rate	State	Х				
19	Long Term Care Bacterial Pneumonia Admission Rate	State	Х				
20	Prevalence of Pressure Ulcers	State	Х	Х			Х
21	Annual Monitoring for Patients on Persistent Medications (MPM)	HEDIS®	Х				
22 & 23	Antidepressant Medication Management (AMM)	HEDIS®	Х	Х	Х	Х	Х

#	Performance Measure	Specification Source	Quality Monitoring	P4P	Yrl	Yr2	Yr3
24	Medication Monitoring for Patients with Schizophrenia	State	Х				
25	Colorectal Cancer Screening (COL)	HEDIS®	Х				
26	Breast Cancer Screening (BCS)	HEDIS®	Х				
27	Cervical Cancer Screening (CCS) (Administrative Method Only)	HEDIS®	Х				
28	Adult BMI Assessment (ABA) (Administrative Method Only)	HEDIS®	Х				
29	Access to Member's Assigned PCP	State	Х	Х	Х	Х	Х
30	Retention Rate for Long Term Care (LTC) and DD	State	Х	Х		Х	Х
& 31	Enrollees Served in the Community						

## **Baselines for Year 1 Pay for Performance Measures**

Measure#	Name	Numerator Desc	Numerator	Denominator Desc	Denominator	Percentage
	Follow Up with Mental Health Provider					
	within 30 Days After Initial Behavioral Health	l ·				
03	Diagnosis	30 days of Initial BHD	1,550	Eligible Population	3,073	50.44%
	Follow-Up After Hospitalization for Mental					
04	Illness	Follow up within 7 days	608	Eligible Population	1,267	47.99%
		Follow up within 30 days	823	Eligible Population	1,267	64.96%
		Ago 10 20, Dontal Visit during				
06	Annual Dental Visit	Age 19-20; Dental Visit during	100	Eligible Population	743	25 579/
06	Allitual Delital Visit	the measurement year	190	Eligible Population	743	3 25.57%
		Age 21 and older; Dental Visit				
		during the measurement year	7.158	Eligible Population	31,436	5 22.77%
		ading the medal cinete year		- Inglore reparation		
		All ages; Dental Visit during the				
		measurement year	7.348	Eligible Population	32,179	22.83%
				- Inglore reparation		22.03/6
		DD only: Age 19-20; Dental Visit during the measurement				
		year	196	Eligible DD Population	595	31.26%
		DD only: Age 21 and older;		Ligible DD Fopulation	393	31.20%
		Dental Visit during the				
		measurement year	1 760	Eligible DD Population	6,740	26.11%
		incusurement year	1,700	Ligible DD i opulation	0,740	20.1176
		DD only: All ages; Dental Visit				
		during the measurement year	1.946	Eligible DD Population	7,335	26.53%
		augeeasareee year		Members 18-75 with	,,,,,,,	20.5370
8A-C	Comprehensive Diabetes Care	Hemoglobin (HbA1c) Testing	4,859	Diabetes	6,347	76.56%
			<del> </del>		1	<u> </u>
		DD Only: Hemoglobin (HbA1c)		DD only: Members 18-75		
		Testing	321	with Diabetes	462	69.48%
			1	Members 18-75 with	T	
		Nephropathy	4,768	Diabetes	6,347	75.12%
				Members 18-75 with		<b> </b>
		LDL-C screening	4,758	Diabetes	6,347	74.96%
	Comprehensive Diabetes Care Admin	Statin Therapy (80% of Eligible		Members 18-75 with		T
8D-E	Method	days)	2,750	Diabetes	6,137	44.81%
	-	ACE/ARB Therapy (80% of	1	Members 18-75 with	<u> </u>	<del> </del>
		Eligible days)	2 729	Diabetes	6,342	43.03%
L		Linguage days	2,723	12.40000	0,342	43.03/0

Measure#	Name	Numerator Desc	Numerator	Denominator Desc	Denominator	Percentage	
		ACE/ARB Therapy (80% of		Members 19 and older			
9A-C	Congestive Heart Failure	Eligible days)	1,322	with CHF	3,640	36.32%	
		Beta Blocker (80% of eligible		Members 19 and older			
		days)	580	with CHF	1,669	34.75%	
				Members 19 and older			
		Diuretic (80% of eligible days)	1,357	with CHF	3,612	37.57%	
		Cholesteral Testing during		Members 19 and older			
10A-C	Coronary Artery Disease	measurement year	2,881	with CAD	3,828	75.26%	
		Received Statin 80% of enrolled		Members 19 and older			
		time	1,352	with CAD	3,646	37.08%	
		Received ACE/ARB 80% of		Members 19 and older			
		enrolled time	1,117	with CAD	3,735	29.91%	
	Persistence of Beta-blocker Treatment After	Persistant Beta Blocker		Discharged alive/AMI			
10D	a Heart Attack	treatment	11	diagnosis	21	52.38%	
				Acute inpatient	<u> </u>		
	Pharmacotherapy Management of COPD	Dispensed a system		discharges and ED visits			
11A-B	Exacerbation	corticosteroid within 14 days	331	for COPD	520	63.65%	
				Acute inpatient			
		Dispensed a bronchodilator		discharges and ED visits			
		within 30 days	408	for COPD	520	78.46%	
	Use of Spiromotry Testing in the Assessment	Nowly diagnosed CORD who		Eligible Population with			
11C	and Diagnosis of COPD	received Spirometry testing	63	newly diagnosed COPD	212	29.72%	
110		received Spirometry testing		newly diagnosed col b	212	29.72/6	
12	Ambulatory Care	Outpatient Visits	29 583	Member months	371,793	79 57	**Rate per 1000
12	This did to ty ear to			DD only: member	3,1,733	, , , , , , , , , , , , , , , , , , , ,	nate per 1000
		DD only: Outpatient Visits	5,518	months	66,850	82.54	**Rate per 1000
					<u> </u>		<u>_</u>
		ED Visits	12,050	Member months	371,793	32.41	**Rate per 1000
				DD only: member			
		DD only: ED Visits	2,448	months	66,850	36.62	**Rate per 1000
		Ambulatory Care visit with a			<u> </u>	<b>_</b>	 
	Amulatory Care Follow-up with a Provider	provider within 14 days of ED		ED visits for Eligible			
13	within 14 Days of Emergency Dept Visit	visit	8,302	Population	21,040	39.46%	
		Ambulatory Care visit with a			1	<u> </u>	
	Amulatory Care Follow-up with a Provider	Provider within 14 days of		Inpatient Discharges for			
16	within 14 Days of Inpatient Discharge	Inpatient Discharge	3,019	Eligible Population	6,361	47.46%	
				<del> </del>	·	)	
20	Prevalence of Pressure Ulcers	ON HOLD	0	<u> </u>	C	)	<u> </u>

Measure#	Name	Numerator Desc	Numerator	Denominator Desc	Denominator	Percentage
				Eligible Population newly		
		Efffective Acute Phase		diagnosed with		
22 - 23	Antidepressant Medication Management	Treatment (at least 84 days)	83	depression	178	46.63%
				Eligible Population newly		
		Efffective Continuation Phase		diagnosed with		
		Treatment (at least 180 days)	61	depression	178	34.27%
			]			
		Ambulatory or Preventive Care		Eligible Population (who		
29	Access to member's Assigned PCP	visit with PCP	12,723	had a PCP in meas. year)	14,488	87.82%